A61K 2039/627
Characterised by the linker
Official title: {characterised by the linker}
A61K2039/627 (Characterised by the linker) appears on 453 US grants and 717 published applications in this corpus.
Search patents in A61K- Granted patents
- 453
- Published applications
- 717
- Assignees
- 373
- Inventors
- 1,339
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 2 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 4 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 10 | 0 |
| 1998 | 10 | 0 |
| 1999 | 6 | 0 |
| 2000 | 8 | 0 |
| 2001 | 7 | 1 |
| 2002 | 3 | 5 |
| 2003 | 3 | 14 |
| 2004 | 6 | 15 |
| 2005 | 1 | 9 |
| 2006 | 5 | 12 |
| 2007 | 9 | 17 |
| 2008 | 2 | 12 |
| 2009 | 9 | 25 |
| 2010 | 10 | 21 |
| 2011 | 5 | 16 |
| 2012 | 7 | 15 |
| 2013 | 11 | 19 |
| 2014 | 13 | 26 |
| 2015 | 25 | 40 |
| 2016 | 21 | 52 |
| 2017 | 26 | 33 |
| 2018 | 30 | 47 |
| 2019 | 33 | 31 |
| 2020 | 37 | 50 |
| 2021 | 22 | 41 |
| 2022 | 19 | 39 |
| 2023 | 30 | 53 |
| 2024 | 30 | 44 |
| 2025 | 23 | 53 |
| 2026 | 13 | 27 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for inducing immune tolerance8 Sep 2026US 12,728,155 B2Anokion SA
- Therapeutic anticancer neoepitope vaccine4 Aug 2026US 12,697,377 B2Nykode Therapeutics ASA
- Alphavirus neoantigen vectors and interferon inhibitors16 Jun 2026US 12,653,883 B2Seattle Project Corp.
- Anti-parasitic immunological compositions9 Jun 2026US 12,648,993 B2Board of Regents of the University of Nebraska
- Individualized vaccines for cancer2 Jun 2026US 12,642,844 B2BioNTech SE
- Modified virus-like particles of cmv10 Sep 2026US 2026/0263612 A1Saiba GmbH
- Vaccines targeting pseudomonas aeruginosa10 Sep 2026US 2026/0265312 A1Evaxion Biotech A/S
- Modified biotin-binding protein, fusion proteins thereof and applications10 Sep 2026US 2026/0265313 A1Children's Medical Center Corporation
- Peptide linkers for modulating antigen immune response in cancer vaccines27 Aug 2026US 2026/0248899 A1Northwestern University
- Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response27 Aug 2026US 2026/0248912 A1Barinthus Biotherapeutics North America, Inc.
Most cited
By later US patents
- Recombinant toxin fragments113US 6,461,617 B1Microbiological Research Authority · 2002
- Saponin-antigen conjugates and the use thereof99US 5,583,112 ACambridge Biotech Corporation · 1996
- Pneumococcal polysaccharide conjugate vaccine98US 5,623,057 AMerck & Co., Inc. · 1997
- Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency89US 4,695,624 AMerck & Co., Inc. · 1987
- Stimulation of hematopoietic cells in vitro83US 6,258,597 B1Point Therapeutics, Inc. · 2001